The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s demonstrating significant efficacy in clinical trials for treating obesity. Unlike some existing weight loss solutions, retatrutide appears to deliver a significant substantial loss in body mass and improve metabolic functio